Ramm Pharma (TSE:RAMM)
:RAMM
Want to see TSE:RAMM full AI Analyst Report?
RAMM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)118.29K
Market Cap
C$1.79M
Enterprise ValueC$866.77K
Total Cash (Recent Filing)C$985.37K
Total Debt (Recent Filing)C$61.30K
Price to Earnings (P/E)―
Beta-2.57
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces ongoing interest burden and financial distress risk, giving the firm structural flexibility to manage cash burn or pursue strategic options without large fixed financing costs. This conservative capital structure is a durable buffer while turnaround efforts proceed.
Improving Cash Flow TrendAlthough still negative, operating and free cash flow have materially improved versus prior years, indicating the company has begun reducing burn. A sustained improvement in cash generation would materially lower external financing needs and improve long-term viability if continued.
Periods Of Higher Gross MarginNotable gross margin improvement in 2024 suggests the company can achieve better unit economics via pricing, mix, or cost control. If these drivers are durable and scaled, they offer a path to margin recovery and more sustainable operating leverage over the medium term.
Bears Say
Declining RevenueA sharp and persistent revenue decline reduces scale while fixed costs remain, impairing the firm's ability to absorb expenses and invest in growth. Without a clear, sustainable revenue recovery, structural competitiveness and long-term product viability are at risk.
Severe Negative ProfitabilityExtremely negative EBIT and net margins indicate the core business is losing money at a large magnitude. This structural unprofitability will continue to erode capital and requires substantive operational change or revenue restoration to become sustainable over the next several months.
Equity ErosionA dramatic drop in shareholders' equity weakens the balance sheet buffer, increases insolvency and dilution risk, and constrains the company's ability to fund R&D, manufacturing or commercial expansion without dilutive or costly external financing.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.79M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Jun 30, 2026 which is in 40 days.
How were Ramm Pharma’s earnings last quarter?
Currently, no data Available
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---